Stevanato Group reported record revenue of €1,104 million for fiscal year 2024, a 2% increase from the prior year, driven by 6% growth in the Biopharmaceutical and Diagnostic Solutions (BDS) segment. Revenue from high-value solutions increased 15% to €422.3 million, representing 38% of total company revenue.
Despite the revenue growth, the full-year gross profit margin decreased to 27.4% from 31.3% in 2023, primarily due to vial destocking, lower gross profit from the Engineering segment, and short-term inefficiencies from new manufacturing facility start-ups. Operating profit margin for fiscal 2024 was 14.6%, with diluted earnings per share at €0.43.
For fiscal year 2025, Stevanato Group introduced guidance expecting revenue between €1.160 billion and €1.190 billion. Adjusted EBITDA is projected to be between €288.5 million and €301.8 million, and adjusted diluted EPS between €0.50 and €0.54, which includes an estimated €4.5 million tariff-related impact to operating profit. Capital expenditures are forecast between €250 million and €280 million, with free cash flow anticipated to be negative €40 million to negative €60 million.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.